Genocea Biosciences Inc. (GNCA): Stock price stood at $5.02 on 07/28/20

SVB Leerink announced it was Initiated coverage of Genocea Biosciences Inc. in a research note on November 15, 2019. The analysts assigned an Outperform rating to the stock. Stifel rated the stock as a Buy in a research noted published on July 08, 2019. Needham rated the stock as a Buy in a research note published on March 01, 2019.

Sonsini Peter W., the 10% Owner of Genocea Biosciences Inc., bought 3.15 million shares at the valuation of $2.25 during an exchange that occurred on Jul 24, which implies that Sonsini Peter W. is holding 10,376,936 shares at the estimation of $7,090,335 dependent on the most recent closing price.

In another transaction, on Jul 24, 10% Owner of Genocea Biosciences Inc., Walker Paul Edward, bought 3.15 million shares at the price of $2.25. After this activity, Walker Paul Edward now keeps 10,376,936 shares of Genocea Biosciences Inc., esteemed at $7,090,335 with the most recent shutting price.

GNCA Recent Trade

The share price of GNCA descended by -$0.51 during the exchanging session on 07/28/20 to exchange at $5.02. Genocea Biosciences Inc. stock has an exchanging volume of 2.81 million shares, which is high, contrasted with its 3-months average volume of 811.46K shares. Its market capitalization has now reached to $111.49M.

GNCA Past Trading Activity

The market tends to become urbane often, in any event, for prepared investors and traders. In any event, when a merchant got what he/she had expected, the market occasionally chooses to move the other way. This instability leads a few traders questioning and re-thinking their moves. This is the reason becoming acquainted with past price performance, just as both long and short time period, is significant. If we look the past performance, during the last one week, GNCA price has rose by 84.56%. In the course of past three months sees the stock go up around 125.11%, while it has gain 136.79% over the past six months and 142.51% since the start of the year.

GNCA Earning History

Earnings per share are the amount of profit that a company produces during a specific period, which is usually defined as a quarter (three calendar months) or a year. In recent quarter of (Sep 2020), the firm recorded a revenue of 906.0 million. For that equivalent quarter, Genocea Biosciences Inc. posted -$0.39 earnings per share (EPS) which was above the consensus estimate of -$0.4 by $0.01, which represents to an expansion by 2.50%.

GNCA Price Performance

Let us presently take a gander at a portion of its probable help and opposition resistance. Late research on Genocea Biosciences Inc. has seen its stock exchanging -12.70% underneath its three-month high price. A glance at the opposite side additionally observes stock exchanging +188.51% above its three-month low. A more extensive look sees GNCA exchanging -12.70% beneath its 52-week high and 356.36% above from its 52-week low price.

GNCA Instability & Beta Factor

The Volatility of a stock means that the stock’s drop or increase in the event that the more extensive market drops or rushes. A beta score higher than 1 implies that a stock is profoundly unpredictable while underneath 1 implies that the Volatility of a stock is low. If we look trading Volatility. Its 7-day Volatility is around 24.37%, while it has a month to month instability of 13.16%. The company has an ATR (Average True Range) of 0.46 and a beta factor of 2.49.

Leave a Comment